Results 61 to 70 of about 2,967,291 (296)

Small bowel metastasis during organ preservation in patients with esophageal squamous cell carcinoma: case report and literature review

Frontiers in Oncology
BackgroundFor patients with locally advanced esophageal squamous cell carcinoma (ESCC) who achieve a clinical complete response (cCR) after comprehensive treatment, organ preservation and observation-waiting strategies provide a more conservative ...
Qinxing Cao, Qinxing Cao, Hejiang Lu, Hejiang Lu, Liangbo Niu, Xiaofang Zhao, Li Yan, Yisha Liu, Minghui Pang, Minghui Pang   +9 more
doaj   +1 more source

Clinical Complete Remission of An Advanced Gastric Adenocarcinoma After Camrelizumab Plus Chemotherapy Followed by Camrelizumab Plus Capecitabine: A Case Report

Frontiers in Oncology, 2021
We report a rare case of PDL1-negative advanced gastric adenocarcinoma that improved significantly after camrelizumab plus chemotherapy followed by camrelizumab plus capecitabine as first-line therapy.
Jieheng Lin, Jianying Yang, Wenping Wang, Xiaotong Lin, Yang Cao   +4 more
doaj   +1 more source

Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma. [PDF]

, 2014
BackgroundCanine cutaneous T-cell lymphoma (CTCL) is an uncommon disease for which efficacious therapies are lacking. The novel anticancer nucleotide prodrug VDC-1101 (formerly known as GS-9219) has shown efficacy in dogs with multicentric lymphoma.
Burgess, KE, Burton, JH, Morges, MA, Saba, CF, Thamm, DH, Vail, DM   +5 more
core   +2 more sources

Gemcitabine, Docetaxel, Melphalan, Carboplatin as Part of Sequential Cycles of High‐Dose Chemotherapy With Autologous Hematopoietic Stem‐Cell Rescue for Multiply Relapsed/Refractory Pediatric Germ Cell Tumors

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Although most malignant germ cell tumors (GCTs) are highly curable with cisplatin‐based therapy, options for patients with multiply relapsed/refractory disease remain limited. For this population, we report the first pediatric use of gemcitabine, docetaxel, melphalan, and carboplatin (GemDMC) as part of sequential cycles of high‐dose ...
Maria Frost, Olayinka Okeleji, Amr Elgehiny, Douglas Harrison, Cynthia Herzog, Jeremy Connors, Demetrios Petropoulos, Priti Tewari, Dristhi Ragoonanan, Yago Nieto, Irtiza N. Sheikh   +10 more
wiley   +1 more source

Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study [PDF]

, 2018
Background: Few studies have compared the efficacy of switching to adalimumab in the real-life setting in plaque psoriasis patients. Objective: To evaluate the effect of adalimumab in psoriasis patients previously treated with other biologics.
Armesto, Burmester, Carrera, Davison, Edson-Heredia, Elm, Gisondi, Gisondi, Gisondi, Gordon, Gossec, Gossec, Gottlieb, Griffiths, Gupta, Honda, Kurd, Lernia, Lernia, López-Ferrer, Lümig, Menter, Menter, Menter, Mrowietz, Nestle, Ortonne, Papoutsaki, Papp, Papp, Papp, Papp, Salvarani, Sbidian, Simone, Strober, Talamonti, Talamonti, Talamonti, Vandenbroucke, Vollenhoven   +40 more
core   +1 more source

COMPLETE CLINICAL RESPONSE OF RECTAL CANCER TO CHEMORADIOTHERAPY: TACTICS

Problems in oncology, 2017
We analyzed literature data and our results of preoperative radiotherapy for 179 patients with resectable rectal cancer T2-4N0-2M0. The purpose of the study was to analyze the complete clinical response to chemoradiotherapy for rectal cancer. The results showed the advantages of monitoring patients with complete clinical response before total ...
Oleg Kit, Yuriy Gevorkyan, Natalya Soldatkina, Marina Gusareva, Dmitriy Kharagezov, Anton Milakin, Sergey Ilchenko   +6 more
openaire   +1 more source

CPX‐351 in High‐Risk Relapsed Pediatric Acute Leukemia: Real‐World Phase 1 Data Establishing the FDA‐Approved Dose

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background/Objectives Outcomes for pediatric relapsed/refractory (R/R) acute myeloid leukemia (AML) remain dismal. CPX‐351, a liposomal formulation of cytarabine and daunorubicin, may have less off‐target toxicities than traditional chemotherapies and has shown improved outcomes for adults with newly diagnosed therapy‐related AML.
Jonathan D. Bender, Lauren Pommert, Lori R. Backus, Andrea Bidwell, Courtney Blank, Erin H. Breese, Karen C. Burns, Adam Lane, Lynn H. Lee, Benjamin Mizukawa, Robin E. Norris, Maureen M. O'Brien, Daniel Peck, Christine Phillips, Thomas D. Ryan, Jennifer Young, Michael Absalon, John P. Perentesis   +17 more
wiley   +1 more source

Development and Validation of a Nomogram to Predict the Probability of Breast Cancer Pathologic Complete Response after Neoadjuvant Chemotherapy: A Retrospective Cohort Study

Frontiers in Surgery, 2022
BackgroundThe methods used to predict the pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) have some limitations. In this study, we aimed to develop a nomogram to predict breast cancer pCR after NAC based on convenient and ...
Yijun Li, Jian Zhang, Bin Wang, Huimin Zhang, Jianjun He, Ke Wang   +5 more
doaj   +1 more source

Topotecan-vincristine-doxorubicin in stage 4 high risk neuroblastoma patients failing to achieve a complete metastatic response to rapid COJEC : a SIOPEN study [PDF]

, 2018
Purpose : Metastatic response to induction therapy for high-risk neuroblastoma is a prognostic factor. In the International Society of Paediatric Oncology Europe Neuroblastoma (SIOPEN) HR-NBL-1 protocol, only patients with metastatic complete response ...
Amoroso, L, Brock, P, Castel, V, Erminio, G, Garaventa, A, Grp, Siopen, Haupt, R, Ladenstein, R, Laureys, G, Luksch, R, Makin, G, Pasquet, M, Pearson, A. D. J, Thomas, C, Valteau-Couanet, D   +14 more
core   +2 more sources

Improving the Evaluation and Management of Transfusion‐Related Iron Overload in Children, Adolescents, and Young Adults Following Cancer Treatment or Hematopoietic Stem Cell Transplantation

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Transfusion‐related iron overload (TRIO) is a late effect of therapy impacting survivors of childhood cancer and hematopoietic stem cell transplantation (HSCT) who receive frequent packed red blood cell (pRBC) transfusions. Surprisingly, there are no accepted guidelines to assist providers in identifying and treating at‐risk ...
Luke Gingell, Allison Close, Guoli Zhou, Troy C. Quigg   +3 more
wiley   +1 more source